The present invention provides isolated anti-human NKG2D monoclonal
antibodies useful for therapeutic applications in humans. Typically, the
antibodies are fully human or humanized to minimize the risk for immune
responses against the antibodies when administered to a patient.
Preferred antibodies include human monoclonal antibodies MS and 21F2. As
described herein, other antigen-binding molecules such as, e.g.,
antigen-binding antibody fragments, antibody derivatives, and
multi-specific molecules, can be designed or derived from such
antibodies.